Matoke® Pharma’s Managing Director, Alan Westwood, writes for Pharmafield on investment in antibiotic research

Pharmafield, “The UK as a global leader in antimicrobial resistance” , 15th April 2019 Alan Westwood, Matoke® Pharma’s Managing Director, writes in Pharmafield discussing the medical need, the UK policy environment and the requirements both from the UK Government and the pharmaceutical industry to overcome the global challenge of antimicrobial resistance. “The pharmaceutical and biotechnology industry must be bold and … Read More

Matoke® Pharma Covered In The Telegraph On Antibiotic Research

The Telegraph, ‘As superbugs threaten to create a global crisis, why are pharmaceutical companies shying away from antibiotics research?’, 14th April 2019 Alan Westwood, Matoke® Pharma’s Managing Director, is featured in The Telegraph discussing the challenges of antibiotic research and the need for new treatments to combat the rise of global superbugs. Matoke® Pharma is working to develop novel antimicrobial … Read More

Matoke® Pharma welcomes UK Government’s 5-Year AMR Strategy

Matoke® Pharma welcomes the UK Government’s new 5-year national action plan to tackle antimicrobial resistance (AMR), published January 2019. Focus on developing and bringing to market new treatments like Reactive Oxygen® is essential to meeting the global AMR threat. Matoke® welcomes the plan’s commitment to: Shift towards value-based pricing for antimicrobials Make AMR a priority for the Accelerated Access Pathway, … Read More

Former Bayer Global VP Takes Reins at Antimicrobial Biotech Matoke® Pharma

Press Release: Former Bayer Global VP Takes Reins at Antimicrobial Biotech Matoke® Pharma British biotech company Matoke® Holdings Ltd has announced the appointment of Alan Westwood, a former Vice President at international pharmaceutical giant Bayer, as the Managing Director of Matoke® Pharma to lead on the pharmaceutical development of its Reactive Oxygen® technology. Westwood spent 35 years at Bayer Health Care, … Read More

Lords praise Reactive Oxygen® as Innovative Wound Treatment in Parliament

Press Release:Lords praise Reactive Oxygen® as Innovative Wound Treatment in Parliament Matoke Holdings’ Reactive Oxygen® technology was hailed in the House of Lords yesterday as an innovative product with the potential to transform wound care in the NHS. In a debate on improving NHS standards in wound treatment, Lord Colwyn outlined the efficacy of Reactive Oxygen® in treating hospital spread … Read More

Matoke Holdings Calls for Fast Track Process to Combat AMR Threat in Parliament

Press Release: MATOKE CALLS FOR FAST TRACK PROCESS TO COMBAT ANTIMICROBIAL RESISTANCE THREAT  Matoke Holdings has called on Government to provide a fast-track process to get new drugs to market to combat the global threat of antimicrobial resistance (AMR), at a meeting of key parliamentarians. Representing small and medium-sized companies, Ian Staples, Chief Executive of British biotech Matoke Holdings, called on … Read More

Matoke Holdings Ltd™ urges government to prioritise AMR in the Industrial Strategy

Press Release: Matoke Holdings Ltd™ urges government to prioritise AMR in the Industrial Strategy Matoke Holdings™, a British biotechnology company that has developed a new generation of antimicrobials based on its Reactive Oxygen® technology platform, has urged the Government to prioritise the fight against antimicrobial resistance (AMR) in its flagship Industrial Strategy. In a written submission to the consultation on the … Read More

Reactive Oxygen® officially recognised by the NHS through Public Health England (PHE) guidance for common infections

Press Release: Reactive Oxygen® officially recognised by the NHS through Public Health England (PHE) guidance for common infections Matoke Holdings, the British biotech company developing a new generation of antimicrobials, is delighted to announce its patent-protected Reactive Oxygen® technology is officially recognised in the latest Public Health England (PHE) guidance, ‘Management and Treatment of Common Infections Antibiotic Guidance For Primary Care’.  … Read More